Company intelligence / Profile preview

Endominance

Ownership: Private
Development stage: Commercial

Overview

Endominance has developed proprietary digital tools such as the Cognitive Biomarker™ platform and the COSEC Assessment for early detection of cognitive and behavioral risk factors. These solutions are designed to empower individuals with actionable insights about their mental and physical well-being. The company focuses on prevention, early intervention, and personalized wellness rather than pharmaceutical interventions or clinical trials.[1][2][3]

Therapeutic areas: OtherPsychiatryNeurology
Modalities: DeviceNon-pharmacological therapyDigital diagnostic tool
Industry: Digital Health Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships disclosed. The company mentions working with partner organizations but does not specify names.[1]

Beyond the preview

Go deeper on Endominance.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endominance.

Explore the full profile